Estado nutricional y rendimiento académico en estudiantes de 5 años de edad de una institución educativa de Independencia-2022

El presente trabajo de investigación tuvo como objetivo general, determinar la relación que existe entre el estado nutricional y el rendimiento académico en estudiantes de 5 años de edad de una Institución Educativa de Independencia- 2022. La cual se utilizó una metodología con enfoque cuantitativo, de diseño correlacional, de tipo básica - no experimental. contó con una población de 190 estudiantes cuya muestra fue 106 estudiantes de 5 años del turno mañana y tarde, así mismo, se aplicó la técnica mediante la observación y el instrumento utilizado fue la guía de observación . Los instrumentos se dieron por la prueba Rho de Spearman, dicha prueba paso por la validación de juicio de expertos quienes certificaron su aplicabilidad. La obtención de resultado llego a la conclusión que existe una correlación entre ambas variables de estudio, el Rho de Spearman p= 0,811 lo que nos da como significado una relación moderada entre las variables de estudio, con una significancia de 0,000 (p< 0,05), por lo que se puede deducir que el estado nutricional si se relaciona con el rendimiento académico en los estudiantes de 5 años de edad de una Institución educativa de Independencia-2022

The Octopus Sign-A New HRCT Sign in Pulmonary Langerhans Cell Histiocytosis.

Background: Fibrosis in pulmonary Langerhans cell histiocytosis (PLCH) histologically comprises a central scar with septal strands and associated airspace enlargement that produce an octopus-like appearance. The purpose of this study was to identify the octopus sign on high-resolution computed tomography (HRCT) images to determine its frequency and distribution across stages of the disease. Methods: Fifty-seven patients with confirmed PLCH were included. Two experienced chest radiologists assessed disease stages as early, intermediate, or late, as well as the lung parenchyma for nodular, cystic, or fibrotic changes and for the presence of the octopus sign. Statistical analysis included Cohen's kappa for interrater agreement and Fisher's exact test for the frequency of the octopus sign. Results: Interobserver agreement was substantial for the octopus sign (kappa = 0.747). Significant differences in distribution of the octopus sign between stages 2 and 3 were found with more frequent octopus signs in stage 2 and fewer in stage 3. In addition, we only found the octopus sign in cases of nodular und cystic lung disease. Conclusions: The octopus sign in PLCH can be identified not only on histological images, but also on HRCT images. Its radiological presence seems to depend on the stage of PLCH

Association of Markers of Inflammation, the Kynurenine Pathway and B Vitamins with Age and Mortality, and a Signature of Inflammaging

Under embargo until: 2022-06-12Background Inflammation is a key feature of aging. We aimed to (i) investigate the association of 34 blood markers potentially involved in inflammatory processes with age and mortality and (ii) develop a signature of “inflammaging.” Methods Thirty-four blood markers relating to inflammation, B vitamin status, and the kynurenine pathway were measured in 976 participants in the Melbourne Collaborative Cohort Study at baseline (median age = 59 years) and follow-up (median age = 70 years). Associations with age and mortality were assessed using linear and Cox regression, respectively. A parsimonious signature of inflammaging was developed and its association with mortality was compared with 2 marker scores calculated across all markers associated with age and mortality, respectively. Results The majority of markers (30/34) were associated with age, with stronger associations observed for neopterin, cystatin C, interleukin (IL)-6, tumor necrosis factor alpha (TNF-α), several markers of the kynurenine pathway and derived indices KTR (kynurenine/tryptophan ratio), PAr index (ratio of 4-pyridoxic acid and the sum of pyridoxal 5′-phosphate and pyridoxal), and HK:XA (3-hydroxykynurenine/xanthurenic acid ratio). Many markers (17/34) showed an association with mortality, in particular IL-6, neopterin, C-reactive protein, quinolinic acid, PAr index, and KTR. The inflammaging signature included 10 markers and was strongly associated with mortality (hazard ratio [HR] per SD = 1.40, 95% CI: 1.24–1.57, p = 2 × 10−8), similar to scores based on all age-associated (HR = 1.38, 95% CI: 1.23–1.55, p = 4 × 10−8) and mortality-associated markers (HR = 1.43, 95% CI: 1.28–1.60, p = 1 × 10−10), respectively. Strong evidence of replication of the inflammaging signature association with mortality was found in the Hordaland Health Study. Conclusion Our study highlights the key role of the kynurenine pathway and vitamin B6 catabolism in aging, along with other well-established inflammation-related markers. A signature of inflammaging based on 10 markers was strongly associated with mortality.acceptedVersio

The ESA Hera Mission : Detailed Characterization of the DART Impact Outcome and of the Binary Asteroid (65803) Didymos

Funding Information: To achieve these objectives, Milani is carrying two scientific payloads, the ASPECT visual and near-infrared (Vis-NIR) imaging spectrometer and the VISTA thermogravimeter aimed at collecting and characterizing volatiles and dust particles below 10 μm. Additionally, navigation payloads include a visible navigation camera and lidar. The Milani consortium is composed of entities and institutions from Italy, the Czech Republic, and Finland. The consortium Prime is Tyvak International, responsible for the whole program management and platform design, development, integration, testing, and final delivery to the customer. Politecnico di Torino is tasked with defining requirements and performing thermal, radiation, and debris analysis. Politecnico di Milano is responsible for mission analysis and GNC. Altec will support the Ground Segment architecture and interface definition. Centro Italiano per la Ricerca Aerospaziale (CIRA) is responsible for the execution of the vehicle environmental campaign. HULD contributes to developing the mission-specific software. VTT is the main payload (ASPECT hyperspectral imager) provider and is supported by the following entities dealing with ASPECT-related development: University of Helsinki (ASPECT calibration); Reaktor Space Lab (ASPECT Data Processing Unit development), Institute of Geology of the Czech Academy of Sciences (ASPECT scientific algorithms requirements and testing); and Brno University of Technology (ASPECT scientific algorithms development). INAF-IAPS is the secondary Payload (VISTA, dust detector) provider. Funding Information: The Mission PI is appointed by ESA and is the primary interface to ESA. The Hera SMB consists of the ESA Hera Project Scientist (ESA PS), the Mission PI, and the Hera Advisory Board, consisting of four mission advisors. The Mission PI chairs the HIT and is supported by the Hera Advisory Board. The tasks of the Hera SMB are 1. advising the Hera mission project team on all aspects related to the Hera mission objectives; 2. ensuring that the WGs’ activities cover the needs of the Hera mission; 3. providing recommendations to ESA concerning the membership in the HIT; and 4. implementing the Publication Policy. Funding Information: Hera is the ESA contribution to the AIDA collaboration. Hera, Juventas, Milani, and their instruments are developed under ESA contract supported by national agencies. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 870377 (project NEO-MAPP), the CNRS through the MITI interdisciplinary programs, ASI, CNES, JAXA, the Academy of Finland project no. 335595, and was conducted with institutional support RVO 67985831 of the Institute of Geology of the Czech Academy of Sciences. M.L., E.P., P.T .and E.D. are grateful to the Italian Space Agency (ASI) for financial support through Agreement No. 2022-8-HH.0 in the context of ESA’s Hera mission. We are grateful to the whole Hera team, including Working Group core members and other contributors for their continuous efforts and support. Their names can be found on the following website: https:// www.heramission.space/team. Publisher Copyright: © 2022. The Author(s). Published by the American Astronomical Society.Hera is a planetary defense mission under development in the Space Safety and Security Program of the European Space Agency for launch in 2024 October. It will rendezvous in late 2026 December with the binary asteroid (65803) Didymos and in particular its moon, Dimorphos, which will be impacted by NASA’s DART spacecraft on 2022 September 26 as the first asteroid deflection test. The main goals of Hera are the detailed characterization of the physical properties of Didymos and Dimorphos and of the crater made by the DART mission, as well as measurement of the momentum transfer efficiency resulting from DART’s impact. The data from the Hera spacecraft and its two CubeSats will also provide significant insights into asteroid science and the evolutionary history of our solar system. Hera will perform the first rendezvous with a binary asteroid and provide new measurements, such as radar sounding of an asteroid interior, which will allow models in planetary science to be tested. Hera will thus provide a crucial element in the global effort to avert future asteroid impacts at the same time as providing world-leading science.Peer reviewe

Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58

Aim To assess the associations between baseline glucose-lowering agents (GLAs) and cardiorenal outcomes with dapagliflozin versus placebo in the DECLARE-TIMI 58 study. Materials and methods DECLARE-TIMI 58 assessed the cardiorenal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. This post hoc analysis elaborates the efficacy and safety outcomes by baseline GLA for treatment effect and GLA-based treatment interaction. Results At baseline, 14 068 patients (82.0%) used metformin, 7322 (42.7%) sulphonylureas, 2888 (16.8%) dipeptidyl peptidase-4 inhibitors, 750 (4.4%) glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and 7013 (40.9%) insulin. Dapagliflozin reduced the composite of cardiovascular death (CVD) and hospitalization for heart failure (HHF) versus placebo regardless of baseline GLA, with greater benefit in the small group of patients with baseline use of GLP-1 RAs (HR [95% CI] 0.37 [0.18, 0.78] vs. 0.86 [0.75, 0.98] in GLP-1 RA users vs. non-users,P-interaction= .03). The overall HR for major adverse cardiovascular events (CVD, myocardial infarction or ischaemic stroke) was 0.93 (95% CI 0.84, 1.03) with dapagliflozin versus placebo, with no interaction by baseline GLA (P-interaction> .05). The renal-specific outcome was reduced with dapagliflozin versus placebo in the overall cohort (HR [95%CI] 0.53[0.43-0.66]), with no interaction by baseline GLA (P-interaction> .05). All of these outcomes were similar in those with versus those without baseline metformin use. Conclusions The effects of dapagliflozin on cardiorenal outcomes were generally consistent regardless of baseline GLA, with consistent benefits regardless of baseline metformin use. The potential clinical benefit of combining sodium-glucose co-transporter-2 inhibitors with GLP-1 RAs, given some evidence of cardiovascular risk reduction with both classes, should be explored further

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

BACKGROUND: End-stage renal disease is associated with a high risk of cardiovascular events. It is unknown, however, whether mild-to-moderate kidney dysfunction is causally related to coronary heart disease (CHD) and stroke. METHODS: Observational analyses were conducted using individual-level data from 4 population data sources (Emerging Risk Factors Collaboration, EPIC-CVD [European Prospective Investigation into Cancer and Nutrition-Cardiovascular Disease Study], Million Veteran Program, and UK Biobank), comprising 648 135 participants with no history of cardiovascular disease or diabetes at baseline, yielding 42 858 and 15 693 incident CHD and stroke events, respectively, during 6.8 million personyears of follow-up. Using a genetic risk score of 218 variants for estimated glomerular filtration rate (eGFR), we conducted Mendelian randomization analyses involving 413 718 participants (25917 CHD and 8622 strokes) in EPIC-CVD, Million Veteran Program, and UK Biobank. RESULTS: There were U-shaped observational associations of creatinine-based eGFR with CHD and stroke, with higher risk in participants with eG FR values 105 mL.min(-1).1.73 m(-2), compared with those with eG FR between 60 and 105 mL.min(-1).1.73 m(-2). Mendelian randomization analyses for CHD showed an association among participants with eGFR 105 mL.min(-1).1.73 m(-2). Results were not materially different after adjustment for factors associated with the eGFR genetic risk score, such as lipoprotein(a), triglycerides, hemoglobin Alc, and blood pressure. Mendelian randomization results for stroke were nonsignificant but broadly similar to those for CHD. CONCLUSIONS: In people without manifest cardiovascular disease or diabetes, mild-to-moderate kidney dysfunction is causally related to risk of CHD, highlighting the potential value of preventive approaches that preserve and modulate kidney function

Discovery of common and rare genetic risk variants for colorectal cancer.

To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome-wide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P < 5 × 10-8, bringing the number of known independent signals for CRC to ~100. New signals implicate lower-frequency variants, Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, long noncoding RNAs and somatic drivers, and support a role for immune function. Heritability analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies enabling rare variant analysis will improve understanding of biology underlying this risk and influence personalized screening strategies and drug development.Goncalo R Abecasis has received compensation from 23andMe and Helix. He is currently an employee of Regeneron Pharmaceuticals. Heather Hampel performs collaborative research with Ambry Genetics, InVitae Genetics, and Myriad Genetic Laboratories, Inc., is on the scientific advisory board for InVitae Genetics and Genome Medical, and has stock in Genome Medical. Rachel Pearlman has participated in collaborative funded research with Myriad Genetics Laboratories and Invitae Genetics but has no financial competitive interest

I care by...

The Care research group at the Royal College of Art (RCA) was conceived in the last week of June 2020, a month after the killing of George Floyd by police in Minnesota, an act which catalysed global protests on systemic racism and police brutality. In the UK, tens of thousands of protesters took to the streets to show solidarity with demonstrators in the US. Coinciding with the easing of the lockdown restrictions imposed to manage the coronavirus, the marches shone a light on the government’s failure to protect Black, Asian and Minority Ethnic people from the disproportionate risk posed by COVID- 19, and on the police’s increased use of stop and search in areas with large BAME populations. The pandemic has shone the harshest of lights on the question of care in the age of neoliberalism: who gets it; who needs it; who does it; who controls it. The Care research group, comprising staff and postgraduate researchers within the School of Arts and Humanities at the RCA, works in this light. Over the course of a year, as the inequalities of the virus were becoming all too clear, the group regularly came together via Zoom to reflect on: the question of how to care for the human body in the technical-patriarchal societies the virus has re-inscribed; the ‘un-doing’ of what Judith Butler describes as the binary of vulnerability and resistance; the politically-transformative potential of prioritising care (rooted in empathy, solidarity, kinship) over capitalist gain; the activation of creative research practices (including but by no means limited to writing, looking, painting, drawing, filming, performing, collecting, assembling, curating, making public) as means of caring/transforming. The group’s activities through the year of trying, failing, and trying again to care for its work and members are gathered in a co-authored Declaration of Care, published here, and expanded upon with attention to some of the methods group members developed in their research through practice. The Declaration was recited in a participatory performance with invited artist Jade Montserrat on 10 March 2021. Over the course of a two-hour webinar, participants including members of the public were invited to draw alongside Montserrat with whatever materials they had to hand as they listened to texts on the vulnerabilities of bodies, the structuring of care within institutions, and the tactile, sensory, healing qualities of creative practice. This book includes a selection of the participants’ drawings, a Reader comprising the texts that were shared, and Montserrat’s drawings created through the performance. Ahead of the performance, Montserrat delivered an address to the Care research group which looked back on a lifetime of calling for a kind of care that was never provided. Excerpts from Montserrat’s address are included here too, alongside a text and image which reflect on the group’s affective reactions to the experience of listening to it, titled Episode. The Declaration is a list of methods (approaches, processes, techniques), an enumeration of how Care research group members have worked, and would like to work: ‘I care by…’. This is a statement which has reverberated throughout the year, which bears repeating, which resounds still. Gemma Blackshaw, Care research group convenor, 2020–202

National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio : a pooled analysis of 458 population-based studies in Asian and Western countries

Background: Although high-density lipoprotein (HDL) and non-HDL cholesterol have opposite associations with coronary heart disease, multi-country reports of lipid trends only use total cholesterol (TC). Our aim was to compare trends in total, HDL and nonHDL cholesterol and the total-to-HDL cholesterol ratio in Asian and Western countries. Methods: We pooled 458 population-based studies with 82.1 million participants in 23 Asian and Western countries. We estimated changes in mean total, HDL and non-HDL cholesterol and mean total-to-HDL cholesterol ratio by country, sex and age group. Results: Since similar to 1980, mean TC increased in Asian countries. In Japan and South Korea, the TC rise was due to rising HDL cholesterol, which increased by up to 0.17 mmol/L per decade in Japanese women; in China, it was due to rising non-HDL cholesterol. TC declined in Western countries, except in Polish men. The decline was largest in Finland and Norway, at similar to 0.4 mmol/L per decade. The decline in TC in most Western countries was the net effect of an increase in HDL cholesterol and a decline in non-HDL cholesterol, with the HDL cholesterol increase largest in New Zealand and Switzerland. Mean total-to-HDL cholesterol ratio declined in Japan, South Korea and most Western countries, by as much as similar to 0.7 per decade in Swiss men (equivalent to similar to 26% decline in coronary heart disease risk per decade). The ratio increased in China. Conclusions: HDL cholesterol has risen and the total-to-HDL cholesterol ratio has declined in many Western countries, Japan and South Korea, with only a weak correlation with changes in TC or non-HDL cholesterol.Peer reviewe

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements